Augurix raises CHF 3 million to further develop program on Celiac and Crohn’s Disease
27 Jan 2014
Augurix SA (“Augurix”), announced today it has successfully completed a round of financing by raising CHF 3 million from private investors.
The successful financing of CHF 3 million was fully subscribed by new private investors. The company will call on these funds in two tranches according to its financial requirements. The new funds, along with existing cash resources, will enable Augurix to expand the marketing of its products, and further advance its clinical and pre-clinical medical diagnostic devices pipeline. These resources will mainly support the regulatory submission in the USA of Simtomax®, a rapid test for the early screening of Celiac Disease, and support the development of a program aiming at developing a new oral contrast agent dedicated to the early stratification of patients suffering from pre-fibrotic Inflammatory Bowel Diseases (IBD).
Get the press release